MSACL 2019 US Abstract

Quantitation of Intact Proteins in Human Plasma using Top-Down Parallel Reaction Monitoring-MS

Daojing Wang
Newomics Inc.

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Daojing Wang (Presenter) Newomics Inc.

Presenter Bio: Dr. Daojing Wang is Founder and CEO of Newomics Inc. Dr. Wang founded Newomics Inc. in August 2011 while a Career Scientist and Principal Investigator at Lawrence Berkeley National Laboratory (LBNL), where he had worked since 2002. Dr. Wang launched Newomics in September 2013 to further its technology development and commercialization. Dr. Wang has been continuously serving as a principal investigator for multiple research grants from NIH, DOE, NASA, and CBCRP. Dr. Wang is the co-inventor of multiple issued and pending patents including M3 emitters, MEA chips, and senescence chips, which together lay the foundation for Newomics’ platforms and solutions for precision medicine.

Relevant Financial Disclosures (within past 24 months) Honorarium/Expenses Newomics Inc. Grant/Research Support Newomics Inc. Committee/Board/Advisory Board Newomics Inc. Stock/Bonds Newomics Inc. Salary Newomics Inc. Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Conflict mitigation IN PROCESS.

Direct quantitation of proteins in complex biological matrices by mass spectrometry remains a challenge. Here, we describe a novel top-down parallel reaction monitoring-mass spectrometry (PRM-MS) assay, enabled by microflow LC-nanospray MS using a silicon microfluidic LC-MS chip. We demonstrated direct analysis of intact proteins such as somatropin in human plasma, achieving sensitivity (0.1-1.0 fmole) and speed (1-5 min) on par with enzyme-linked immunosorbent assay (ELISA). Further development of the technology will enable direct and top-down clinical proteomics for precision medicine.